1599-5453 Contact Us KO
Neuromodulation

Deep Brain Stimulation

Deep Brain Stimulation

Deep brain stimulation (DBS) is a neurosurgical treatment that modulates abnormal neural circuit activity by inserting electrodes into specific brain regions and delivering high-frequency electrical stimulation.

2026-03-29

At a Glance

DBS is the standard surgical treatment for Parkinson's disease, essential tremor, and dystonia that do not adequately respond to pharmacotherapy. Electrodes are inserted into the subthalamic nucleus (STN) or globus pallidus internus (GPi) to deliver continuous electrical stimulation. In Parkinson's disease, it can improve motor symptoms by approximately 50-70% and reduce medication doses by 30-50% [1]. As a reversible procedure, it has the advantage that stimulation parameters can be changed or the device can be removed.

Definition and Overview

Deep brain stimulation (DBS) is a neurosurgical procedure in which microelectrodes are stereotactically inserted into specific target nuclei of the brain, and continuous high-frequency electrical stimulation is delivered from an implantable pulse generator (IPG) placed subcutaneously in the chest to modulate abnormal neural circuit activity.

Since its initial introduction for tremor treatment by Benabid et al. in 1987, its efficacy for Parkinson's disease, essential tremor, and dystonia has been demonstrated in large-scale randomized controlled trials [1][3]. It has been performed in more than 200,000 patients worldwide, and indications continue to expand [4].

Principles and Mechanism

Mechanism of Action

The precise mechanism of DBS has not been fully elucidated, but it is understood that high-frequency (130-180 Hz) electrical stimulation modulates abnormal neural activity patterns in the target region. Previously explained as a 'functional lesion' effect, current understanding proposes multiple mechanisms including suppression of pathological oscillations, alteration of neurotransmitter release, and promotion of neuroplasticity [4].

Stimulation Targets

  • Subthalamic nucleus (STN): The most common target for Parkinson's disease. Excellent for motor symptom improvement and medication dose reduction.
  • Globus pallidus internus (GPi): Used for dyskinesia control in Parkinson's disease and dystonia treatment [3].
  • Ventral intermediate nucleus (VIM): The standard target for essential tremor treatment.

Indications

Parkinson's Disease

Moderate to advanced Parkinson's disease with motor fluctuation and dyskinesia during pharmacotherapy is the most representative indication. The EARLYSTIM study demonstrated that DBS produced superior outcomes compared to pharmacotherapy alone even in patients with early-onset motor complications [2].

Essential Tremor

VIM-DBS is effective for severe essential tremor refractory to medication (propranolol, primidone), with significant tremor reduction in approximately 80-90% of patients.

Dystonia

GPi-DBS has been reported to improve symptoms by approximately 50-70% in generalized or segmental dystonia [3]. The best outcomes are seen in primary dystonia caused by DYT1 gene mutation.

Expanded Indications

Research is ongoing for OCD, treatment-resistant depression, Tourette syndrome, and epilepsy, with some indications having received limited approval [4].

Surgical Procedure

Preoperative Evaluation

A multidisciplinary team (neurology, neurosurgery, neuropsychology, psychiatry) comprehensively assesses surgical suitability. Brain MRI confirms target nucleus location, and neuropsychological testing evaluates cognitive function.

Electrode Implantation

Electrodes are precisely inserted into the target nucleus using a stereotactic frame or robot-assisted system. Microelectrode recording electrophysiologically confirms the target location. For Parkinson's disease, awake surgery to observe real-time symptom changes was traditional, but image-guided procedures under general anesthesia have been increasing recently.

Pulse Generator Implantation

The IPG is implanted subcutaneously below the clavicle in the chest and connected to the intracranial electrodes via an extension wire passing under the scalp.

Programming

Programming begins 2-4 weeks postoperatively to optimize stimulation parameters (voltage, frequency, pulse width, stimulation contacts). Finding optimal settings may take several months.

Treatment Outcomes

Parkinson's Disease

In large-scale randomized controlled trials, STN-DBS improved motor symptoms in the off-medication state by approximately 50-70% [1]. Dyskinesia in the on-medication state decreases by approximately 60-70%, and daily levodopa dose can be reduced by approximately 30-50%. In long-term follow-up beyond 5 years, efficacy for tremor and rigidity is maintained, but effects on gait disturbance and speech disorders tend to diminish over time.

Dystonia

After GPi-DBS, the Burke-Fahn-Marsden dystonia score improves by approximately 50-70%, and the effect appears gradually over several months, which differs from Parkinson's disease [3].

Adverse Effects and Complications

Surgery-related

Intracranial hemorrhage (1-2%), infection (3-5%), lead migration, and skin erosion have been reported [4].

Stimulation-related

Depending on stimulation settings, dysarthria, muscle contractions, paresthesia, and balance disturbance may occur, but most can be managed by adjusting stimulation parameters. Mood changes and impulse control disorders have been reported in some patients, necessitating regular follow-up.

Recent Advances

Technological advances are progressing rapidly, including directional leads, adaptive DBS (aDBS), and MRI-compatible devices [5]. Adaptive DBS analyzes brain signals in real time and delivers stimulation only when needed, with expected benefits of extended battery life and reduced side effects.

Frequently Asked Questions

Parkinson's disease patients who do not adequately respond to pharmacotherapy or who have severe medication side effects (dyskinesia) are the most representative candidates. It is also performed for essential tremor and medication-refractory dystonia. Generally, outcomes are best in levodopa-responsive Parkinson's disease with preserved cognitive function [1].

All brain surgery carries risks, but the rate of serious DBS complications is relatively low. Intracranial hemorrhage at approximately 1-2%, infection at approximately 3-5%, and lead migration have been reported [4]. Safety is high when performed at experienced centers, and the reversibility of the procedure is a major advantage.

Medication is not completely discontinued. DBS supplements medication efficacy and helps reduce medication doses. Research shows that levodopa dose can be reduced by approximately 30-50% after STN-DBS, with approximately 50-70% improvement in motor symptoms [1].

Non-rechargeable batteries last approximately 3-5 years, and rechargeable batteries approximately 15-25 years. When battery life is exhausted, the pulse generator (IPG) in the chest can be replaced through a relatively simple procedure, while the intracranial electrodes remain in place [5].

Most modern DBS systems are MR-conditional products. However, there are restrictions on imaging conditions (magnetic field strength, coil type, SAR limits, etc.), so MRI must only be performed after consulting with the DBS medical team. MRI may be restricted with older devices.

References

  1. [1] Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W (2006). "A randomized trial of deep-brain stimulation for Parkinson's disease." New England Journal of Medicine, 355: 896-908. DOI PubMed
  2. [2] Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N (2013). "Neurostimulation for Parkinson's disease with early motor complications." New England Journal of Medicine, 368: 610-622. DOI PubMed
  3. [3] Kupsch A, Benecke R, Müller J, Trottenberg T, Schneider GH, Poewe W, Eisner W, Wolters A, Müller JU, Deuschl G (2006). "Pallidal deep-brain stimulation in primary generalized or segmental dystonia." New England Journal of Medicine, 355: 1978-1990. DOI PubMed
  4. [4] Lozano AM, Lipsman N, Bergman H, Brown P, Chabardes S, Chang JW, Matthews K, McIntyre CC, Schlaepfer TE, Bhatt M (2019). "Deep brain stimulation: current challenges and future directions." Nature Reviews Neurology, 15: 148-160. DOI PubMed
  5. [5] Krauss JK, Lipsman N, Aziz T, Boutet A, Brown P, Chang JW, Davidson B, Grill WM, Hariz MI, Horn A (2021). "Technology of deep brain stimulation: current status and future directions." Nature Reviews Neurology, 17: 75-87. DOI PubMed

Related Articles

Vagus Nerve Stimulation
Deep Brain StimulationDBSParkinson's Disease TreatmentDystonia TreatmentEssential TremorNeuromodulationBrain Surgery

This content is provided for medical information purposes only and cannot replace professional medical advice. If you have symptoms, please consult a specialist.

Are you concerned about related symptoms?

Get an accurate diagnosis at OSANG Neurosurgery.

02-514-8887 Contact Us